--- title: "Mereo BioPharma Q3 net loss narrows 17% to $5.86 million" type: "News" locale: "en" url: "https://longbridge.com/en/news/304856804.md" description: "Mereo BioPharma reported a 17% narrowing of its Q3 net loss to $5.86 million, with revenue at $800,000 and R&D expenses dropping 51% to $2.09 million. The company holds $26.1 million in cash, sufficient for operations through late 2027. Regulatory discussions with Ultragenyx regarding setrusumab are ongoing, while work with Sentynl aims for an early-2027 Phase 3 launch for alvelestat." datetime: "2026-11-09T13:08:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/304856804.md) - [en](https://longbridge.com/en/news/304856804.md) - [zh-HK](https://longbridge.com/zh-HK/news/304856804.md) generator: "portal-rs" --- # Mereo BioPharma Q3 net loss narrows 17% to $5.86 million - Mereo BioPharma’s third-quarter 2026 net loss narrowed 17% year over year to $5.86 million. \* Revenue reached $800,000, while research and development expenses fell 51% year over year to $2.09 million. \* Cash and cash equivalents totaled $26.1 million at September 30, expected to fund operations into late 2027. \* Regulatory discussions with partner Ultragenyx continue to assess a potential path forward for setrusumab in pediatric osteogenesis imperfecta. \* Work with Sentynl continues to refine alvelestat’s Phase 3 trial design, with preparations targeting a potential early-2027 study launch. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090800PRIMZONEFULLFEED9872887) on November 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [MREO.US](https://longbridge.com/en/quote/MREO.US.md) - [RARE.US](https://longbridge.com/en/quote/RARE.US.md) ## Related News & Research - [Profit Outlook Raised Could Change The Case For Zeta Global Stock](https://longbridge.com/en/news/306379536.md) - [USD.AI: USD.AI unlocks at least 147.12 million CHIP - Sep 2027](https://longbridge.com/en/news/306378017.md) - [What Veeva Systems Stock AI Training Integration Means For Shareholders](https://longbridge.com/en/news/306379375.md) - [Wall St Week Ahead-'Black Friday' brings consumer spending into focus for AI-rocked market](https://longbridge.com/en/news/306395310.md) - [Space Exploration Technologies (SPCX) Gets A New Hiring Twist As Musk Eyes Top AI Talent](https://longbridge.com/en/news/306383945.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**